Prostate-specific Membrane Antigen (PSMA) expression in cervical carcinoma

Conditions: C53.9
Cervix uteri, unspecified

Registration Number: DRKS00023289

Lead Sponsor: niversitätsklinikum FreiburgKlinik für Frauenheilkunde

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 100

Inclusion Criteria

Patients with a histologically secured invasive cervical carcinoma are included in this study . The cancerous pre-stages surrounding the Tumor (cervical intraepithelial neoplasia, adenocarcinoma in situ) are also investigated.

Exclusion Criteria

- no declaration of consent
- other oncological disease
- adenosquamous, neuroendocrine (large or small cell), clear-line or serous-papillary carcinoma
- Cytostatic or radiotherapy administered before tissue sampling

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of the PSMA expression within the cervix and cervical carcinoma and its malignant precursors on previously removed tissue, using immunohistochemistry and immunofluorescence, as well as proteomic analyses if necessary.

Secondary Outcome Measures

Name	Time	Method
Depending on the PSMA status (both tumor cells and Tumorneovasculature):<br>- overall survival (OS)<br>- Disease free survival (dfs)<br>Clinical parameters:<br>- Age at time of diagnosis, menopause status, FIGO stage at time of diagnosis, distant metastasis, body mass index, family history, birth rate, postoperative radio- or chemotherapy.<br>Histopathological parameters:<br>- pTNM stage, histological subtype (squamous cell carcinoma), grading, lymph vessel, vein and perineural vaginal infiltration, deep stroma invasion (>66%), three dimensional tumor size in centimeters, HPV status (positive/negative).<br>